Gløersen Marthe, Kjeken Ingvild, Tveter A T, Kazemi Amirhossein, Sexton Joseph, Dziedzic Krysia, Felson David T, Stamm Tanja A, Guermazi Ali, Hermann-Eriksen Merete, Sæther M I, Lundby Kristine, Esperø E L, Olsen Monika, Norheim K B, Fister Edle Berg, Hoff Mari, Uleberg Jorunn Kvalø, Midtgard Irina Petrovna, Andreassen Therese, Sjølie Dag, Sletten Heidi, Hammer H B, Haugen Ida K
Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
Oslo Metropolitan University, Oslo, Norway.
Osteoarthr Cartil Open. 2024 Nov 19;7(1):100542. doi: 10.1016/j.ocarto.2024.100542. eCollection 2025 Mar.
Our primary objectives are to assess whether intraarticular corticosteroid injections are superior to saline injections with regards to thumb base pain after 4 weeks, and to compare the efficacy of steroid injections, saline injections, and an occupational therapy intervention on thumb base pain after 12 weeks in people with painful inflammatory osteoarthritis (OA) of the first carpometacarpal (CMC-1) joint.
In this three-armed, double-blind, randomized multicenter trial, 354 participants with painful inflammatory CMC-1 OA from six Norwegian hospitals are recruited. Participants are randomized 1:1:1 to intraarticular steroid or saline injections in the CMC-1 joint or a multimodal occupational therapy intervention. The primary outcomes are thumb base pain measured on a numeric rating scale (NRS, range: 0-10) after 4 weeks and 12 weeks. Key secondary outcomes include synovitis by Magnetic Resonance Imaging (MRI) after 4 weeks and hand function by the Measure of Activity Performance of the Hand (MAP-Hand) questionnaire after 12 and 24 weeks. Other secondary outcomes are synovitis by clinical examination and ultrasound, measures of pain, function, stiffness, and health-related quality of life, and direct and indirect costs. Adverse events are recorded at each visit. The duration of the randomized controlled trial is 24 weeks, followed by an 80-week open-label observational phase to investigate the long-term efficacy and safety of repeated steroid injections and the occupational therapy intervention.
The results from this trial will have important clinical implications and influence future guidelines on OA management of the CMC-1 joint.
EU-CT 2023-505254-17-00, NCT06084364.
我们的主要目的是评估关节内注射皮质类固醇在4周后对于拇指基部疼痛是否优于注射生理盐水,以及比较类固醇注射、生理盐水注射和职业治疗干预对患有第一腕掌关节(CMC-1)疼痛性炎症性骨关节炎(OA)的患者在12周后拇指基部疼痛的疗效。
在这项三臂、双盲、随机多中心试验中,招募了来自挪威六家医院的354名患有疼痛性炎症性CMC-1 OA的参与者。参与者按1:1:1随机分配至CMC-1关节内注射类固醇或生理盐水或接受多模式职业治疗干预。主要结局是在4周和12周后用数字评分量表(NRS,范围:0-10)测量的拇指基部疼痛。关键次要结局包括4周后通过磁共振成像(MRI)评估的滑膜炎以及12周和24周后通过手部活动表现测量问卷(MAP-Hand)评估的手部功能。其他次要结局是通过临床检查和超声评估的滑膜炎、疼痛、功能、僵硬和健康相关生活质量的测量指标以及直接和间接成本。每次就诊时记录不良事件。随机对照试验的持续时间为24周,随后是为期80周的开放标签观察期,以研究重复类固醇注射和职业治疗干预的长期疗效和安全性。
该试验的结果将具有重要的临床意义,并影响未来关于CMC-1关节OA管理的指南。
EU-CT 2023-505254-17-00,NCT06084364。